

Bioactive Cycloartane-Type Triterpene Glycosides from *Astragalus elongatus*

İhsan Çalış^{a,c}, Matej Barbič^b, and Guido Jürgenliemk^{b,*}

^a Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, TR-06100 Ankara, Turkey

^b Universität Regensburg, Institut für Pharmazie, Lehrstuhl Pharmazeutische Biologie, Universitätsstr. 31, D-93053 Regensburg, Germany. Fax: +49 94 1943 49 90. E-mail: guido.juergenliemk@chemie.uni-regensburg.de

^c Present address: Near East University, Faculty of Pharmacy, Department of Pharmacognosy and Pharmaceutical Botany, Nicosia, Turkish Republik of Northern Cyprus

* Author for correspondence and reprint requests

Z. Naturforsch. **63c**, 813–820 (2008); received April 10/July 17, 2008

Together with two known cycloartane-type glycosides, askendosides D (3-*O*-[α -arabinopyranosyl-(1 \rightarrow 2)- β -xylopyranosyl]-6-*O*- β -xylopyranosyl-cycloastragenol, **2**) and G (3-*O*-[α -arabinopyranosyl-(1 \rightarrow 2)- β -xylopyranosyl]-16-*O*- β -glucopyranosyl-3 β ,6 α ,16 β ,24(*R*),25-pentahydroxycycloartane, **3**), also a new monodesmosidic cycloartane-type glycoside, elongatoside (**1**), was isolated from the roots of *Astragalus elongatus* and identified as 3-*O*-[α -arabinopyranosyl-(1 \rightarrow 2)- β -xylopyranosyl]-cycloastragenol. All structures were unambiguously determined by means of spectroscopic and spectrometric methods (1D and 2D NMR, ESI-MS). The isolated compounds were tested for the inhibition of proliferation and ICAM-1 expression *in vitro* using the human microvascular endothelial cell line (HMEC-1). **1** showed weak activity in the ICAM-1 assay.

Key words: *Astragalus elongatus*, Cycloartane-Type Glycosides, Endothelium